Articles

The past decade has given us several breakthrough treatment options for a complex and serious malignancy, multiple myeloma (MM). Read More ›

Multiple myeloma (MM) accounts for 10% to 15% of all hematologic malignancies, and is the cause of 20% of the deaths that result from blood and bone cancers. Read More ›

A recent study examined patients’ reactions when they learned for the first time that they carried either a BRCA1 or BRCA2 gene mutation and that these mutations put them at higher risk for breast and ovarian cancer. Read More ›

Although often thought of as a common cancer among elderly men, prostate cancer also strikes patients between the ages of 35 and 50. Read More ›

For some men, exercise may have a positive impact on prostate cancer risk. Read More ›

A study evaluating different ways of helping men consider prostate-specific antigen (PSA) screening shows that the patient’s decision-making process was influenced by the format in which information was offered. Read More ›

For those patients with multiple myeloma whose disease has progressed after being treated with other cancer drugs, the FDA has recently approved a new drug, Pomalyst (pomalidomide). Read More ›

Researchers recently studied the effects of intimate partner violence and childhood sexual abuse on a woman’s levels of depression, perceived stress, and cancer-related well-being. Read More ›

According to a new study, the underlying medical conditions affecting young adults who undergo CT exams are a significantly greater health risk than that of radiation-induced cancer from CT. Read More ›

Researchers compared outcomes among prostate cancer patients treated with surgery and those treated with radiotherapy and discovered that differences in urinary, bowel, and sexual function exist after short-term follow-up. Read More ›